2015 - FROM PASSIVE CONTROL TO ACTIVE ELIMINATION
For World TB Day 2015, ECDC focused on the specific challenges that Europe faces on the road to elimination.
Despite historically low numbers and a significant decline over the last ten years, EU/EEA countries are not all progressing in the same way. The downward trend is influenced by a marked decline of TB in high-priority countries, whereas in some low-incidence countries the notification rates are actually going up. To become the first continent free of tuberculosis, Europe needs to step up its efforts and move from passive control to active elimination.
At the current pace of an annual 6% decline, the EU/EEA will only be free of tuberculosis in the next century. In order to achieve elimination by 2050 for example, Europe would have to cut down cases at least twice as fast.
Europe needs tailored interventions which target each country’s settings. In most low-incidence countries TB rates are stable or going down only very slowly and the majority of patients are of foreign-origin. Countries with high incidence overall face higher rates of re-infection and relapses and report many more MDR TB cases.
The goal to eliminate TB depends on a more efficient use of current tools and interventions, to be complemented by new and more effective ones.
Tuberculosis surveillance and monitoring 2015
Joint Press Release ECDC/WHO Europe: Every day, 1 000 people get sick with tuberculosis in the European Region
2014 – MDR TB AND MDR TB TREATMENT OUTCOMES
For World TB Day 2014, ECDC is focusing on multidrug-resistant tuberculosis (MDR TB), particularly on MDR TB treatment and treatment outcomes.
In the EU/EEA, the treatment success rates of MDR TB patients have remained stable but at a very low level: only one in every three (34%) patients in the reporting EU/EEA countries finishes MDR TB treatment successfully. More than half die, fail treatment or default (stop taking treatment).
MDR and XDR TB patients face much longer treatment, take more drugs, suffer from more side effects and treatment costs are five times higher compared to drug-susceptible TB. Only complete and successful tuberculosis treatment helps to prevent disease transmission and development of resistant strains that lead to the development of extensively drug-resistant TB (XDR TB), which is almost impossible to treat.
Merely 7 of the 21 countries reporting have maintained a mean five-year decline in MDR notification rates and the overall MDR TB treatment success rate remains far below the 70% target defined by the Framework Action Plan to Fight Tuberculosis in the European Union.
TB is slowly declining but MDR and XDR TB pose a serious challenge in the attempt to eliminate TB across Europe, even though the number of reported MDR TB cases seem to decline slowly.
In EU, only 1 in every 3 MDR TB patients has a successful treatment outcome; more than half either die, fail treatment or default (stop taking treatment). XDR TB has even worse treatment outcomes: only 1 in 4 patients finishes treatment successfully.
By not diagnosing and not treating patients with MDR TB early and successfully, we put their live at risk and pave the way for XDR TB.
Only complete and successful tuberculosis treatment helps to prevent disease transmission and development of resistant strains.
Tuberculosis surveillance and monitoring in Europe 2014
Healthcare system factors influencing treatment results of patients with multidrug-resistant tuberculosis – Technical Report
“Tuberculosis cases down by 5% each year but Europe fails to cure majority of multidrug-resistant patients” - Press Release
Monitoring Framework Action Plan to Fight Tuberculosis in the European Union
Management of contacts of MDR TB and XDR TB patients
2013 - EXTRAPULMONARY TB
Tuberculosis surveillance and monitoring in Europe 2013
“Adequate treatment essential to stop TB across Europe – new ECDC/WHO report” – Press release
2012 - URBAN TB
2011 - CHILDHOOD TB